

## **prIME Points™**

- ☒ **Polycythemia vera can be challenging to diagnose with current diagnostic criteria**
- ☒ **Management is individualized according to thrombotic risk, and evidence for choice of first-line cytoreductive therapy needs to be improved**
- ☒ **Patients who are refractory to hydroxyurea have a worse prognosis and need careful consideration**
- ☒ **Novel therapies such as ruxolitinib have the potential to control disease and improve quality of life**